Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Recommendation of "Buy" from Brokerages

Shares of Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) have earned an average rating of "Buy" from the ten analysts that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $29.86.

KURA has been the topic of a number of recent analyst reports. HC Wainwright raised their target price on shares of Kura Oncology from $32.00 to $37.00 and gave the company a "buy" rating in a research note on Thursday, November 21st. Lifesci Capital upgraded shares of Kura Oncology to a "strong-buy" rating in a research report on Tuesday, October 22nd. Cantor Fitzgerald reiterated an "overweight" rating on shares of Kura Oncology in a research report on Monday, December 9th. Jefferies Financial Group decreased their target price on shares of Kura Oncology from $32.00 to $28.00 and set a "buy" rating on the stock in a research report on Thursday, November 21st. Finally, Wedbush reaffirmed an "outperform" rating and set a $37.00 price objective on shares of Kura Oncology in a research note on Monday, November 4th.

Institutional Trading of Kura Oncology

Several large investors have recently modified their holdings of the business. Suvretta Capital Management LLC lifted its holdings in Kura Oncology by 8.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company's stock worth $149,535,000 after buying an additional 583,155 shares during the period. Armistice Capital LLC lifted its stake in Kura Oncology by 14.7% in the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company's stock worth $48,386,000 after acquiring an additional 302,000 shares during the period. Geode Capital Management LLC lifted its stake in Kura Oncology by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company's stock worth $34,798,000 after acquiring an additional 41,535 shares during the period. Franklin Resources Inc. boosted its holdings in Kura Oncology by 1.5% in the third quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company's stock valued at $28,687,000 after acquiring an additional 23,113 shares in the last quarter. Finally, Candriam S.C.A. increased its position in Kura Oncology by 39.2% during the 2nd quarter. Candriam S.C.A. now owns 906,482 shares of the company's stock valued at $18,664,000 after purchasing an additional 255,065 shares during the period.

Kura Oncology Stock Performance

Shares of KURA traded down $0.16 during trading hours on Monday, hitting $8.51. The company's stock had a trading volume of 1,985,243 shares, compared to its average volume of 1,098,068. The company has a market cap of $661.77 million, a price-to-earnings ratio of -3.61 and a beta of 0.75. Kura Oncology has a 52-week low of $8.42 and a 52-week high of $24.17. The business has a 50 day simple moving average of $13.17 and a two-hundred day simple moving average of $17.58. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.